BONCRESA
LaunchmAbdenosumab-mobz
BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
BONCRESA (denosumab-mobz) is rank ligand blocking activity [moa]. First approved in 2025.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BONCRESA (denosumab-mobz) is a monoclonal antibody that blocks RANK ligand to inhibit osteoclast activity and bone resorption. It is approved for the treatment of osteoporosis in patients at risk of fracture. The drug is administered via subcutaneous injection and represents a biosimilar entry into the denosumab market dominated by Amgen's PROLIA.
Launch
Newly launched biosimilar entering a mature market with moderate competitive pressure (30/100); early-stage commercial teams will focus on payer negotiations and market penetration against established reference product.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BONCRESA launch offers entry or growth opportunities in biosimilar commercialization, a high-growth segment of pharma. Roles emphasize payer negotiations, formulary positioning, and physician conversion—distinct skill sets from traditional small-molecule brands. Team size likely remains lean relative to reference product due to lower patient volumes and shared medical infrastructure.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.